Can-Fite BioPharma Ltd. Research and Development Expense
Can-Fite BioPharma Ltd. (CANF) reported Research and Development Expense of $6.69 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-03-26
| Period end | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|
| 2025-12-31 | $6.69M 20-F · filed 2026-03-26 | |
| 2025-06-30 | $3.03M 6-K · filed 2025-08-28 | |
| 2024-12-31 | $5.76M 20-F · filed 2026-03-26 | |
| 2024-06-30 | $2.88M 6-K · filed 2025-08-28 | |
| 2023-12-31 | $5.98M 20-F · filed 2026-03-26 | |
| 2023-06-30 | $3.42M 6-K · filed 2024-08-29 | |
| 2022-12-31 | $7.76M 20-F · filed 2025-04-14 | |
| 2022-06-30 | $3.27M 6-K · filed 2023-08-31 | |
| 2021-12-31 | $9.85M 20-F · filed 2024-03-28 | |
| 2021-06-30 | $3.81M 6-K · filed 2022-08-25 | |
| 2020-12-31 | $11.95M 20-F · filed 2023-03-30 | |
| 2020-06-30 | $7.05M 6-K · filed 2021-08-26 | |
| 2019-12-31 | $10.98M 20-F · filed 2022-03-24 | |
| 2019-06-30 | $3.96M 6-K · filed 2020-08-27 | |
| 2018-12-31 | $6.08M 20-F · filed 2021-03-25 | |
| 2017-12-31 | $5.11M 6-K · filed 2020-06-01 | |
| 2016-12-31 | $6.12M 20-F · filed 2019-03-29 | |
| 2015-12-31 | $3.90M 6-K · filed 2018-08-08 |